New pharmaceutical treatment of gastric MALT lymphoma: Anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib

Current Pharmaceutical Design

Volumn 20, Issue 7, 2014, Pages 1097-1103

  Nakamura, Masahiko ^a   Takahashi, Tetsufumi ^a   Matsui, Hidenori ^a   Takahashi, Shinichi ^b   Murayama, Somay Y ^c   Suzuki, Hidekazu ^d   Tsuchimoto, Kanji ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KYORIN UNIVERSITY   (Japan)

^c NIHON UNIVERSITY   (Japan)

^d KEIO UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Celecoxib; Flk 1; Flt 1; Flt 4; Gastric MALT lymphoma; Lymphangiogenesis; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIBODY; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; PYRAZOLE DERIVATIVE; SULFONAMIDE; VASCULOTROPIN RECEPTOR;

ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; HELICOBACTER INFECTIONS; IMMUNOLOGY; LYMPHOMA, B-CELL, MARGINAL ZONE; MOUSE; STOMACH NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES; CELECOXIB; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; HELICOBACTER INFECTIONS; LYMPHOMA, B-CELL, MARGINAL ZONE; MICE; PYRAZOLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; STOMACH NEOPLASMS; SULFONAMIDES;

EID: 84895156862     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990420     Document Type: Article

References (18)

1. Troch M, Kiesewetter B, Willenbacher W, et al. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue-Lymphoma: a phase II study by the Arbeitsgemeinschaft Medi-kamentose Tumortherapie. Haematologica 2012; [Epub ahead of print]
2. Rezvani AR, Maloney DG. Rituximab resistance. Best Pract. Res Clin Haematol 2011; 24(2): 203-16.
3. Genta RM, Huberman RM, Graham DY. The gastric cardia in Helicobacter pylori infection. Hum Path 1994; 25: 915-9.
4. Morgner A, Lehn N, Andersen LP, et al. Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000; 118: 821-8.
5. Nakamura M, Tsuchimoto K, Matsui H. Relation of Helicobacter heilmannii to gastric mucosal damage as a model of zoonosis between men and pets. Nihon Rinsho 2005; 63 Suppl 11: 605-8.
6. Nakamura M, Murayama SY, Serizawa H, et al. Candidatus Helicobacter heilmannii from cynomolgus monkey brought about gastric low grade MALT lymphoma in C57BL/6 mice. Infect Immun 2007; 75; 1214-22.
7. Nakamura M, Matsui H, Murayama SY, et al. Interaction of VEGF to gastric low grade MALT lymphoma by Helicobacter heilmannii infection in C57BL/6 mice. Inflammopharmacology 2007; 15: 115-8.
8. Nishikawa K, Nakamura M, Takahashi S, et al. Increased apoptosis and angiogenesis in gastric low-grade mucosa-associated lymphoid tissue-type lymphoma by Helicobacter heilmannii infection in C57/BL6 mice. FEMS Immunol Med Microbiol 2007; 50: 268-272.
9. Nakamura M, Takahashi S, Matsui H, et al. Microcirculatory alteration in low-grade mucosa-associated lymphoma by Helicobacter heilmannii infection: its relation to vascular endothelial growth factor and cyclooxygenase-2. J Gastroenterol Hepatol 2008; 23 (Suppl. 2): S157-S160.
10. Sugito M, Araki K, Ogata T. Three-dimensional organization of lymphatics in the dog stomach a scanning electron microscopic study of corrosion casts. Arch Histol Cytol 1996; 59: 61-70.
11. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454, 656-60.
12. Chelly I, Adouni O, Chouaib S, et al. Gastric MALT lymphoma: anatomo-clinical data and outcome of early stage H. pyloriassociated gastric MALT-lymphoma resistant to treatment. La Tunisie médicale 2011; 89: 910-15.
13. Matsui H, Aikawa C, Sekiya Y, Takahashi S, Murayama SY, Nakamura M. Evaluation of antibiotic therapy for eradication of Candidatus Helicobacter heilmannii. Antimicrobial Agent and Chemotherapy 2008; 52: 2988-9.
14. Nakamura M, Matsui H, Takahashi T, et al. Suppression of lymphangiogenesis induced by Flt-4 antibody in gastric low-grade mucosa-associated lymphoid tissue lymphoma by Helicobacter heilmannii infection. J. Gastroenterol. Hepatol. 2010; 25 (Suppl 1): S1-6.
15. Yu L, Wu X, Cheng Z, et al. Interaction between bevacizumab and murine VEGF-A: a reassessment. Invest Ophthalmol Vis Sci 2008; 49, 522-7.
16. Rudge JS, Holash J, Hylton D, et al. Inaugural article: VEGF trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci U S A 2007; 104, 18363-70.
17. Sawaoka H, Tsuji S, Tsujii M, et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999; 79: 1469-77.
18. Saito Y, Suzuki H, Tsugawa H, et al. Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication. PLoS One 2012; 7: e47396.